MX2018012904A - Uso de beta-agonistas del receptor de la hormona tiroidea. - Google Patents
Uso de beta-agonistas del receptor de la hormona tiroidea.Info
- Publication number
- MX2018012904A MX2018012904A MX2018012904A MX2018012904A MX2018012904A MX 2018012904 A MX2018012904 A MX 2018012904A MX 2018012904 A MX2018012904 A MX 2018012904A MX 2018012904 A MX2018012904 A MX 2018012904A MX 2018012904 A MX2018012904 A MX 2018012904A
- Authority
- MX
- Mexico
- Prior art keywords
- agonists
- thyroid beta
- thyroid
- beta
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
Abstract
La presente invención se refiere a métodos útiles para tratar la adrenoleucodistrofia enlazada a X.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662326431P | 2016-04-22 | 2016-04-22 | |
PCT/US2017/029102 WO2017185083A1 (en) | 2016-04-22 | 2017-04-24 | Use of thyroid beta-agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018012904A true MX2018012904A (es) | 2019-01-31 |
Family
ID=60117062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018012904A MX2018012904A (es) | 2016-04-22 | 2017-04-24 | Uso de beta-agonistas del receptor de la hormona tiroidea. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20190134069A1 (es) |
EP (1) | EP3445372A4 (es) |
JP (1) | JP2019515915A (es) |
KR (1) | KR102407053B1 (es) |
CN (3) | CN109641003A (es) |
AU (2) | AU2017252122B2 (es) |
BR (1) | BR112018071559B1 (es) |
CA (1) | CA3021677A1 (es) |
MX (1) | MX2018012904A (es) |
WO (1) | WO2017185083A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017252126B2 (en) | 2016-04-22 | 2023-02-09 | Metabasis Therapeutics, Inc. | Use of thyroid beta-agonists |
US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
WO2023245055A1 (en) * | 2022-06-15 | 2023-12-21 | Viking Therapeutics, Inc. | Thyroid beta-agonist dosing regimens for the treatment of x-ald |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
JP2007524656A (ja) * | 2003-10-23 | 2007-08-30 | セルジーン・コーポレーション | 疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法 |
KR100971695B1 (ko) * | 2004-12-08 | 2010-07-23 | 리비젼 쎄러퓨틱스, 인크. | 레티놀-관련 질환의 치료 방법, 검정법 및 치료용 조성물 |
JPWO2007097289A1 (ja) * | 2006-02-20 | 2009-07-16 | 武田薬品工業株式会社 | 新規医薬 |
WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
US8575207B2 (en) * | 2010-08-16 | 2013-11-05 | Allergan, Inc. | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists |
WO2014178892A1 (en) * | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
RU2017132673A (ru) * | 2015-02-20 | 2019-03-20 | Орегон Хэлт Энд Сайенс Юниверсити | Производные собетирома |
RU2719245C2 (ru) * | 2016-02-29 | 2020-04-17 | Филип Моррис Продактс С.А. | Тара и заготовка с шарнирной крышкой |
CA3024680A1 (en) * | 2016-05-18 | 2017-11-23 | Oregon Health & Science University | Derivatives of sobetirome |
-
2017
- 2017-04-24 US US16/095,224 patent/US20190134069A1/en not_active Abandoned
- 2017-04-24 BR BR112018071559-0A patent/BR112018071559B1/pt active IP Right Grant
- 2017-04-24 JP JP2018555273A patent/JP2019515915A/ja active Pending
- 2017-04-24 AU AU2017252122A patent/AU2017252122B2/en active Active
- 2017-04-24 MX MX2018012904A patent/MX2018012904A/es unknown
- 2017-04-24 CN CN201780038675.7A patent/CN109641003A/zh active Pending
- 2017-04-24 CN CN201910397947.3A patent/CN110200978B/zh active Active
- 2017-04-24 KR KR1020187033321A patent/KR102407053B1/ko active IP Right Grant
- 2017-04-24 CN CN202110804956.7A patent/CN113730421A/zh active Pending
- 2017-04-24 WO PCT/US2017/029102 patent/WO2017185083A1/en active Application Filing
- 2017-04-24 EP EP17786795.9A patent/EP3445372A4/en active Pending
- 2017-04-24 CA CA3021677A patent/CA3021677A1/en active Pending
-
2023
- 2023-04-14 AU AU2023202321A patent/AU2023202321A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2019515915A (ja) | 2019-06-13 |
KR20190017748A (ko) | 2019-02-20 |
CN110200978B (zh) | 2023-10-31 |
KR102407053B1 (ko) | 2022-06-10 |
CN110200978A (zh) | 2019-09-06 |
CN109641003A (zh) | 2019-04-16 |
AU2017252122A1 (en) | 2018-11-15 |
BR112018071559A2 (pt) | 2019-05-14 |
AU2017252122B2 (en) | 2023-02-09 |
WO2017185083A1 (en) | 2017-10-26 |
EP3445372A4 (en) | 2020-03-25 |
CN113730421A (zh) | 2021-12-03 |
US20190134069A1 (en) | 2019-05-09 |
CA3021677A1 (en) | 2017-10-26 |
EP3445372A1 (en) | 2019-02-27 |
BR112018071559B1 (pt) | 2024-02-06 |
AU2023202321A1 (en) | 2023-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020550781A1 (en) | Anti-jagged1 antibodies and methods of use | |
PH12017500877A1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
PH12016501894B1 (en) | Anti-ox40 antibodies and methods of use | |
MX2017005920A (es) | Anticuerpos anti-tim3 y metodos de uso. | |
PH12017500322A1 (en) | Anti-her2 antibodies and immunoconjugates | |
MA40579A (fr) | Anticorps anti-cll-1 et immunoconjugués | |
GB2556286A (en) | Programmable voltage reference | |
MX2017006094A (es) | Anticuerpos anti-interleucina-33 y sus usos. | |
MX2017001981A (es) | Inhibidores de diana de rapamicina en celulas de mamifero de complejo 1 (mtorc1). | |
MX2016015162A (es) | Anticuerpos anti - gpc3 e inmunoconjugados. | |
MX2016009858A (es) | Fusiones anti proteína convertasa subtilisina/kexina tipo 9 (anti-pcsk9)n péptido 1 similar a glucagón (glp-1) y métodos de uso. | |
MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
MX2020012893A (es) | Formulaciones de proteinas. | |
PH12017501022A1 (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
MX2016016233A (es) | Anticuerpos anti-lgr5 y sus usos. | |
MX2018012904A (es) | Uso de beta-agonistas del receptor de la hormona tiroidea. | |
MX2018012900A (es) | Uso de beta-agonistas del receptor de la hormona tiroidea. | |
MX2016015280A (es) | Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso. | |
EP3094347A4 (en) | Methods for enhancing the delivery of active agents | |
WO2016040313A3 (en) | Methods of treating cancer comprising administering a ppar-gamma agonist | |
MX2016009541A (es) | Metodo para tratar vajilla. | |
NZ744340A (en) | Anti-jagged1 antibodies and methods of use | |
IN2014CH00872A (es) | ||
UA98223U (ru) | Высокоэнергетические эко пеллеты |